Skip to main content
Erschienen in: Cancer Immunology, Immunotherapy 4/2009

01.04.2009 | Original Article

Early developmental expression of a normally tumor-associated and drug-inhibited cell surface-located NADH oxidase (ENOX2) in non-cancer cells

verfasst von: NaMi Cho, D. James Morré

Erschienen in: Cancer Immunology, Immunotherapy | Ausgabe 4/2009

Einloggen, um Zugang zu erhalten

Abstract

Full length mRNA to a drug-inhibited cell surface NADH oxidase, tNOX or ENOX2, is present in both non-cancer and cancer cells but is translated only in cancer cells as alternatively spliced variants. ENOX2 is a growth-related protein of the external plasma membrane surface that is shed into the circulation and is inhibited by a series of quinone site inhibitors with anticancer activity. To test the possibility that ENOX2 expression might be important to early stages of non-cancer cell development, the expression of the protein was monitored in chicken embryos during their development. Polyclonal antisera to a 34 kDa human serum form of ENOX2 cross-immunoreactive with the drug-responsive NADH oxidase of chicken hepatoma cells was used. The protein was identified based on drug-responsive enzymatic activities and analyses by western blots. The drug-responsive activity was associated with plasma membranes and sera of early chicken embryos and with chicken hepatoma plasma membranes but was absent from plasma membranes prepared from livers or from sera of normal adult chickens and from late embryo stages. The findings suggest that ENOX2 may fulfill some functions essential to the growth of early embryos which are lost in late embryo stages and absent from normal adult cells but which then reappear in cancer.
Literatur
1.
Zurück zum Zitat Morré DJ, Chueh P-J, Morré DM (1995) Capsaicin inhibits preferentially the NADH oxidase and growth of transformed cells in culture. Proc Natl Acad Sci USA 92:1831–1835PubMedCrossRef Morré DJ, Chueh P-J, Morré DM (1995) Capsaicin inhibits preferentially the NADH oxidase and growth of transformed cells in culture. Proc Natl Acad Sci USA 92:1831–1835PubMedCrossRef
2.
Zurück zum Zitat Morré DJ, Morré DM, Stevenson J, MacKellar WC, McClure D (1995) HeLa plasma membranes bind the antitumor sulfonylurea LY181984 with high affinity. Biochim Biophys Acta 1244:133–140PubMed Morré DJ, Morré DM, Stevenson J, MacKellar WC, McClure D (1995) HeLa plasma membranes bind the antitumor sulfonylurea LY181984 with high affinity. Biochim Biophys Acta 1244:133–140PubMed
3.
Zurück zum Zitat Morré DJ, Kim C, Paulik M, Morré DM, Faulk WP (1997) Is the drug-responsive NADH oxidase of the cancer cell plasma membrane a molecular target for adriamycin? J Biomembr Bioenerg 29:269–280CrossRef Morré DJ, Kim C, Paulik M, Morré DM, Faulk WP (1997) Is the drug-responsive NADH oxidase of the cancer cell plasma membrane a molecular target for adriamycin? J Biomembr Bioenerg 29:269–280CrossRef
4.
Zurück zum Zitat Morré DJ (1998) NADH oxidase: a multifunctional ectoproteins of the eukaryotic cell surface. In: Asard H, Bérczi A, Caubergs R (eds) Plasma membrane redox systems and their role in biological stress and disease. Kluwer Academic Publishers, Dordrecht, The Netherlands, pp 121–156 Morré DJ (1998) NADH oxidase: a multifunctional ectoproteins of the eukaryotic cell surface. In: Asard H, Bérczi A, Caubergs R (eds) Plasma membrane redox systems and their role in biological stress and disease. Kluwer Academic Publishers, Dordrecht, The Netherlands, pp 121–156
5.
Zurück zum Zitat Morré DJ, Morré DM (2003) Cell surface NADH oxidases (ECTO-NOX proteins) with roles in cancer, cellular time-keeping, growth, aging and neurodegenerative disease. Free Radical Res 37:795–808CrossRef Morré DJ, Morré DM (2003) Cell surface NADH oxidases (ECTO-NOX proteins) with roles in cancer, cellular time-keeping, growth, aging and neurodegenerative disease. Free Radical Res 37:795–808CrossRef
6.
Zurück zum Zitat Morré DJ, Merriman R, Tanzer LR, Wu L-Y, Morré DM, MacKellar WC (1995) Inhibition of the NADH oxidase activity of plasma membranes isolated from xenografts and cell lines by the antitumor sulfonylurea, N-(4-methlyphenylsulfonyl)-N′-(4-chlorophenyl)urea (LY181984) correlates with drug susceptibility of growth. Protoplasma 184:203–208CrossRef Morré DJ, Merriman R, Tanzer LR, Wu L-Y, Morré DM, MacKellar WC (1995) Inhibition of the NADH oxidase activity of plasma membranes isolated from xenografts and cell lines by the antitumor sulfonylurea, N-(4-methlyphenylsulfonyl)-N′-(4-chlorophenyl)urea (LY181984) correlates with drug susceptibility of growth. Protoplasma 184:203–208CrossRef
7.
Zurück zum Zitat Morré DJ, Sun E, Geilen C, Wu L-Y, de Cabo R, Krasagakis K, Orfanos CE, Morré DM (1996) Capsaicin inhibits plasma membrane NADH oxidase and growth of human and mouse melanoma lines. Eur J Cancer 32:1995–2003CrossRef Morré DJ, Sun E, Geilen C, Wu L-Y, de Cabo R, Krasagakis K, Orfanos CE, Morré DM (1996) Capsaicin inhibits plasma membrane NADH oxidase and growth of human and mouse melanoma lines. Eur J Cancer 32:1995–2003CrossRef
8.
Zurück zum Zitat Chueh P-J, Kim C, Cho N, Morré DM, Morré DJ (2002) Molecular cloning and characterization of a tumor-associated, growth-related and time-keeping hydroquinone (NADH) oxidase (NOX) of the HeLa cell surface. Biochemistry 41:3732–3741PubMedCrossRef Chueh P-J, Kim C, Cho N, Morré DM, Morré DJ (2002) Molecular cloning and characterization of a tumor-associated, growth-related and time-keeping hydroquinone (NADH) oxidase (NOX) of the HeLa cell surface. Biochemistry 41:3732–3741PubMedCrossRef
9.
Zurück zum Zitat Morré DJ, Caldwell S, Mayorga A, Wu L-Y, Morré DM (1997) NADH oxidase activity from sera altered by capsaicin is widely distributed among cancer patients. Arch Biochem Biophys 342:224–230PubMedCrossRef Morré DJ, Caldwell S, Mayorga A, Wu L-Y, Morré DM (1997) NADH oxidase activity from sera altered by capsaicin is widely distributed among cancer patients. Arch Biochem Biophys 342:224–230PubMedCrossRef
10.
Zurück zum Zitat Morré DJ, Reust T (1997) A circulating form of NADH oxidase activity responsive to the antitumor sulfonylurea N-(4-methlyphenylsulfonyl)-N′-(4-chlorophenyl)urea (LY181984) specific to sera from cancer patients. J Bioenerg Biomemb 29:281–289CrossRef Morré DJ, Reust T (1997) A circulating form of NADH oxidase activity responsive to the antitumor sulfonylurea N-(4-methlyphenylsulfonyl)-N′-(4-chlorophenyl)urea (LY181984) specific to sera from cancer patients. J Bioenerg Biomemb 29:281–289CrossRef
11.
Zurück zum Zitat Kishi T, Morré DM, Morré DJ (1999) The plasma membrane NADH oxidase of HeLa cells has hydroquinone oxidase activity. Biochim Biophys Acta 1412:66–77PubMedCrossRef Kishi T, Morré DM, Morré DJ (1999) The plasma membrane NADH oxidase of HeLa cells has hydroquinone oxidase activity. Biochim Biophys Acta 1412:66–77PubMedCrossRef
12.
Zurück zum Zitat Morré DJ, Pogue R, Morré DM (1999) A multi-functional ubiquinol oxidase of the external cell surface and sera. BioFactors 9:179–187PubMedCrossRef Morré DJ, Pogue R, Morré DM (1999) A multi-functional ubiquinol oxidase of the external cell surface and sera. BioFactors 9:179–187PubMedCrossRef
13.
Zurück zum Zitat Herst PM, Berridge MV (2006) Plasma membrane electron transport: a new target for cancer drug development. Curr Mol Med 6:895–904PubMedCrossRef Herst PM, Berridge MV (2006) Plasma membrane electron transport: a new target for cancer drug development. Curr Mol Med 6:895–904PubMedCrossRef
14.
Zurück zum Zitat Tang X, Tian Z, Chueh P-J, Chen S, Morré DM, Morré DJ (2007) Alternative splicing as the basis for specific localization of tNOX, a unique hydroquinone (NADH) oxidase, to the cancer cell surface. Biochemistry 46:12,337–12346 Tang X, Tian Z, Chueh P-J, Chen S, Morré DM, Morré DJ (2007) Alternative splicing as the basis for specific localization of tNOX, a unique hydroquinone (NADH) oxidase, to the cancer cell surface. Biochemistry 46:12,337–12346
15.
Zurück zum Zitat Hamburger V, Hamilton HL (1951) A series of normal stages in the development of the chick embryo. J Morphol 88:49–92CrossRef Hamburger V, Hamilton HL (1951) A series of normal stages in the development of the chick embryo. J Morphol 88:49–92CrossRef
16.
Zurück zum Zitat Scholz E, Welniak E, Nyholm T, Guo P (1993) An avian hepatoma cell line for the cultivation of infectious laryngotracheitis virus and for the expression of foreign genes with a mammalian promoter. J Virol Methods 43(3):273–286PubMedCrossRef Scholz E, Welniak E, Nyholm T, Guo P (1993) An avian hepatoma cell line for the cultivation of infectious laryngotracheitis virus and for the expression of foreign genes with a mammalian promoter. J Virol Methods 43(3):273–286PubMedCrossRef
17.
Zurück zum Zitat Morre DJ, Morre DM (1989) Preparation of mammalian plasma membranes by aqueous two-phase partition. BioTechniques 7(9):946–958PubMed Morre DJ, Morre DM (1989) Preparation of mammalian plasma membranes by aqueous two-phase partition. BioTechniques 7(9):946–958PubMed
18.
Zurück zum Zitat Wilkinson FE, Kim C, Cho N, Chueh P-J, Leslie S, Moya-Camarena S, Wu L-Y, Morré DM, Morré DJ (1996) Isolation and identification of a protein with capsaicin-inhibited NADH oxidase activity from culture media conditioned by growth of HeLa cells. Arch Biochem Biophys 336:275–282PubMedCrossRef Wilkinson FE, Kim C, Cho N, Chueh P-J, Leslie S, Moya-Camarena S, Wu L-Y, Morré DM, Morré DJ (1996) Isolation and identification of a protein with capsaicin-inhibited NADH oxidase activity from culture media conditioned by growth of HeLa cells. Arch Biochem Biophys 336:275–282PubMedCrossRef
19.
Zurück zum Zitat Chueh P-J, Morré DJ, Wilkinson FE, Gibson J, Morré DM (1997) A 33.5 kDa heat- and protease-resistant NADH oxidase inhibited by capsaicin from sera of cancer patients. Arch Biochem Biophys 342:38–47PubMedCrossRef Chueh P-J, Morré DJ, Wilkinson FE, Gibson J, Morré DM (1997) A 33.5 kDa heat- and protease-resistant NADH oxidase inhibited by capsaicin from sera of cancer patients. Arch Biochem Biophys 342:38–47PubMedCrossRef
20.
Zurück zum Zitat Schreiber H, Ward PL, Rowley DA, Stauss HJ (1988) Unique tumor-specific antigens. Annu Rev Immunol 6:465–482PubMedCrossRef Schreiber H, Ward PL, Rowley DA, Stauss HJ (1988) Unique tumor-specific antigens. Annu Rev Immunol 6:465–482PubMedCrossRef
21.
Zurück zum Zitat Mizejewski GJ (2001) Alpha-fetoprotein structure and function: relevance to isoforms, epitopes, and conformational variants. Exp Biol Med 226:377–408 Mizejewski GJ (2001) Alpha-fetoprotein structure and function: relevance to isoforms, epitopes, and conformational variants. Exp Biol Med 226:377–408
22.
Zurück zum Zitat Lucha PA Jr, Rosen L, Olenwine JA, Reed JF 3rd, Riether RD, Stasik JJ Jr, Khubchandani IT (1997) Value of carcinoembryonic antigen monitoring in curative surgery for recurrent colorectal carcinoma. Dis Colon Rectum 40:145–149PubMedCrossRef Lucha PA Jr, Rosen L, Olenwine JA, Reed JF 3rd, Riether RD, Stasik JJ Jr, Khubchandani IT (1997) Value of carcinoembryonic antigen monitoring in curative surgery for recurrent colorectal carcinoma. Dis Colon Rectum 40:145–149PubMedCrossRef
23.
Zurück zum Zitat Huang JQ, Turbide C, Daniels E, Jothy S, Beauchemin N (1990) Spatiotemporal expression of murine carcinoembryonic antigen (CEA) gene family members during mouse embryogenesis. Development 110:573–588PubMed Huang JQ, Turbide C, Daniels E, Jothy S, Beauchemin N (1990) Spatiotemporal expression of murine carcinoembryonic antigen (CEA) gene family members during mouse embryogenesis. Development 110:573–588PubMed
24.
Zurück zum Zitat Gitlin D, Perricelli A, Gitlin GM (1972) Synthesis of α-fetoprotein by liver, yolk sac, and gastrointestinal tract of the human conceptus. Cancer Res 32(5):979–982PubMed Gitlin D, Perricelli A, Gitlin GM (1972) Synthesis of α-fetoprotein by liver, yolk sac, and gastrointestinal tract of the human conceptus. Cancer Res 32(5):979–982PubMed
25.
Zurück zum Zitat Yagiz K, Morré DJ, Morré DM (2006) Transgenic mouse line overexpressing the cancer-specific tNOX protein has an enhanced growth and acquired drug-response phenotype. J Nutr Biochem 17:750–759PubMedCrossRef Yagiz K, Morré DJ, Morré DM (2006) Transgenic mouse line overexpressing the cancer-specific tNOX protein has an enhanced growth and acquired drug-response phenotype. J Nutr Biochem 17:750–759PubMedCrossRef
26.
Zurück zum Zitat Bearz A, Talamini R, Vaccher E, Spina M, Simonelli C, Steffan A, Berretta M, Chimienti E, Tirelli U (2007) MUC-1 (CA 15–3 antigen) as a highly reliable predictor of response to EGFR inhibitors in patients with bronchioloalveolar carcinoma: an experience on 26 patients. Int J Biol Markers 22:307–311PubMed Bearz A, Talamini R, Vaccher E, Spina M, Simonelli C, Steffan A, Berretta M, Chimienti E, Tirelli U (2007) MUC-1 (CA 15–3 antigen) as a highly reliable predictor of response to EGFR inhibitors in patients with bronchioloalveolar carcinoma: an experience on 26 patients. Int J Biol Markers 22:307–311PubMed
27.
Zurück zum Zitat Braga VM, Gendler SJ (1993) Modulation of Muc-1 mucin expression in the mouse uterus during the estrus cycle, early pregnancy and placentation. J Cell Sci 105(Pt 2):397–405PubMed Braga VM, Gendler SJ (1993) Modulation of Muc-1 mucin expression in the mouse uterus during the estrus cycle, early pregnancy and placentation. J Cell Sci 105(Pt 2):397–405PubMed
28.
Zurück zum Zitat Brown JP, Woodbury RG, Hart CE, Hellström I, Hellström KE (1981) Quantitative analysis of melanoma-associated antigen p97 in normal and neoplastic tissues. Proc Natl Acad Sci USA 78(1):539–543PubMedCrossRef Brown JP, Woodbury RG, Hart CE, Hellström I, Hellström KE (1981) Quantitative analysis of melanoma-associated antigen p97 in normal and neoplastic tissues. Proc Natl Acad Sci USA 78(1):539–543PubMedCrossRef
29.
Zurück zum Zitat Disis M, Pupa SM, Gralow JR, Dittadi R, Menard S, Cheever MA (1997) High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer. J Clin Oncol 15:3363–3367PubMed Disis M, Pupa SM, Gralow JR, Dittadi R, Menard S, Cheever MA (1997) High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer. J Clin Oncol 15:3363–3367PubMed
30.
Zurück zum Zitat Morré DJ, Wilkinson FE, Kim C, Cho N, Lawrence J, Morré DM (1996) Antitumor sulfonylurea-inhibited NADH oxidase of cultured HeLa cells shed into media. Biochim Biophys Acta 1280:197–206PubMedCrossRef Morré DJ, Wilkinson FE, Kim C, Cho N, Lawrence J, Morré DM (1996) Antitumor sulfonylurea-inhibited NADH oxidase of cultured HeLa cells shed into media. Biochim Biophys Acta 1280:197–206PubMedCrossRef
Metadaten
Titel
Early developmental expression of a normally tumor-associated and drug-inhibited cell surface-located NADH oxidase (ENOX2) in non-cancer cells
verfasst von
NaMi Cho
D. James Morré
Publikationsdatum
01.04.2009
Verlag
Springer-Verlag
Erschienen in
Cancer Immunology, Immunotherapy / Ausgabe 4/2009
Print ISSN: 0340-7004
Elektronische ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-008-0577-3

Weitere Artikel der Ausgabe 4/2009

Cancer Immunology, Immunotherapy 4/2009 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.